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Summary
When human cells are stressed during G2, they are
delayed from entering mitosis via a checkpoint medi-
ated by the p38 kinase [1–5], and this delay can be mod-
eled by the selective activation of p38 with anisomycin
[6, 7]. Here, we report, on the basis of live-cell studies,
that 75 nM anisomycin transiently (1 hr) activates p38
which, in turn, rapidly and completely blocks entry
into mitosis for at least 4 hr in all primary, telomerase-
or spontaneously immortalized (p53+ and pRB+) hu-
man cells. However, the same treatment does not delay
entry into mitosis in cancer cells, or the delay in enter-
ing mitosis is shortened, even though it induces a sim-
ilar transient and comparable (or stronger) activation
of p38. Because the primary substrate of p38, the MK2
kinase, is also transiently (1–2 hr) activated by aniso-
mycin in both normal and cancer cells, checkpoint dis-
ruption in transformed cells occurs downstream of
MK2. Finally, observations on isogenic lines reveal
that the duration of the stress checkpoint is shortened
in cells lacking both p53 and pRb and that the constitu-
tive expression of an active H-Ras oncogene in these
cells further attenuates the checkpoint via an ERK1/2-
dependent manner. Thus, transformation leads to at-
tenuation of the p38-mediated stress checkpoint. This
outcome is likely selected for during transformation
because it confers the ability to outgrow normal cells
under stressful in vitro (culture) or in vivo (tumor) envi-
ronments. Our data caution against using cancer cells
to study how p38 produces a G2 arrest.
Results and Discussion
We used two time-lapse light microscopic (LM) assays
to study how the activation of p38 affects the G2-M
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Kingdom.transition. The first is based on the observation that
the cessation of chromosome condensation in late G2
reveals that the cell cycle has been arrested [8]. The sec-
ond is based on the fact that the number of cells entering
mitosis during a given 30 min period can be accurately
determined in monolayer cultures from 103 phase-con-
trast records of cell fields (Figure S1 in the Supplemental
Data available online). (The number of experiments for
our studies and the number of cells examined is tabu-
lated in Table S1.) In both assays, cells entered mitosis
with normal kinetics when treated with only dimethyl
sulfoxide (DMSO) (Figure S2C).
Activating p38 in Normal Cells Rapidly Delays
the G2-M Transition
The antibiotic anisomycin is a well-studied protein-
synthesis inhibitor that activates p38 but not JNK (Fig-
ure 1) at nM concentrations in cultured cells [6, 7] with
minimal effects on protein translation [9, 10]. We found
that the G2 delay induced by anisomycin increased
with increasing drug concentrations (Figure S2A), which
activated correspondingly more p38 (Figure 1; see also
[7]). From these data, we defined an anisomycin concen-
tration (75 nM; Figure S2A) that delayed the G2-M tran-
sition for at least 4 hr in normal human cells (Figure 2A)
without activating JNK kinase (Figure 1). Under this con-
dition, the number of cells entering mitosis falls at least
3-fold within 30 min of anisomycin treatment (Figure 2A),
until it reaches zero by 1 hr. Accordingly, when late G2
hTERT-RPE1 cells were perfused with 75 nM anisomy-
cin early in chromosome condensation, entry into mito-
sis was delayed (Figure 2C; n = 6).
To confirm that this G2 delay requires p38 activity, we
incubated hTERT-RPE1 cultures in 25 mM SB203580,
a potent inhibitor of p38 activation [11], 30 min before
treating them with anisomycin. As expected under this
condition, RPE1 cells entered mitosis after exposure to
75 nM anisomycin, although the combination of drugs
did slightly depress the rate (Figure S2B).
After 4 hr or more in 75 nM anisomycin, normal cells
resumed cycling into mitosis (Figure 2A, Figure S2A).
However, rather than quickly reaching control levels,
the mitotic index increased gradually (Figure S2D),
implying that the activation of p38 stops G2 at that point
at which the drug was applied and that different cells
recover at different rates. Although under our conditions
the mitotic index did not return to control levels, when
normal cells are stressed with agents that have no
long-term, toxic side effects (e.g., nocodazole or os-
motic shock), the mitotic index quickly returns to control
levels [4, 12].
To determine whether p38 activity remains high as
cells slip through the stress checkpoint, we assayed
p38 activity over time in telomerase-immortalized RPE1
and BJ-EN cells exposed continuously to anisomycin. In
both lines, p38 activity rose during the first hour of treat-
ment to levels more than five times that of nontreated
cells, after which it quickly decayed to pretreatment
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duced spike and subsequent decay of p38 activity has
been noted by others [13]. As for osmotic shock [4],
we also found that the inhibition of p38 with SB203580,
1 hr after it was activated with 75 nM anisomycin, did
not significantly accelerate entry into mitosis in RPE1
cells (p = < 0.001; data not shown). Thus, as noted by
Dmitrieva and colleagues [4], although a sudden in-
crease in p38 activity is required for the initiation of
a stress-induced G2 delay, the delay is maintained by
downstream events independent of p38. Several feed-
back control loops are thought to limit the duration of
p38 activation [14], most likely to insure an adequate
response to subsequent stresses.
Figure 1. Seventy-Five Nanomolars of Anisomycin Strongly Acti-
vates p38, but Not JNK, in Both Normal and Cancer Cells in a
Dose-Dependent Fashion
(A) A 30 min treatment with nanomolar concentrations of anisomycin
activates p38 in telomerase-immortalized (hTERT-RPE1) cells, as
well as in fully oncogenic (HeLa) cells. Both p38 and JNK1 and 2
activation were examined in western blots with antibodies against
dually phosphorylated and activated forms of p38 (p38-T*GY*) and
JNK1 and 2 (JNK1 and 2-T*PY*). Equal amounts of protein per gel
lane were loaded. Total p38 antibody blotting (p38) is the loading
control.
(B) The band densities in (A) were measured so that a plot of p38
phosphorylation (y axis, arbitrary units) versus anisomycin concen-
tration (x axis, nM) could be produced. Note that the amount of p38
phosphorylated in HeLa (dotted line) is significantly higher at all
anisomycin concentrations than in RPE1 (solid line).At this point, we can define several characteristics of
the p38-mediated checkpoint pathway in normal cells.
First, when triggered, it stops progression through G2
in minutes. Second, in a normal cell population, the
checkpoint is rigorous: Not one cell out of many thou-
sands was seen to enter mitosis 30 min after the activa-
tion of p38. Third, although p38 activity is required to trig-
ger the G2 delay, downstream events maintain the delay.
Finally, after a variable period, G2 cells resume cycling
into mitosis in the presence of the activating stress.
Activating p38 in Cancer Cells Does Not Delay Entry
into Mitosis, or Delay Is Significantly Reduced
Next, we explored how the activation of p38 affects the
G2-M transition in cancer cells. p38 is readily activated
in many cancer lines [6], including those used in our
study, e.g., CFPAC1 [15], tumorigenic (T)-HEP3, and D
dormant (D)-HEP3 [16]. For HeLa cells, we found that
75 nM anisomycin activated p38 to a much higher level
than it did in nontransformed REP1 cells (Figure 1B).
Yet although anisomycin strongly activates p38 in the
cancer lines examined, cells in these lines continued
to enter mitosis after drug treatment (Figure 2B). In
T-HEP3 and D-HEP3, the rate of entry did not apprecia-
bly change relative to controls, whereas in HeLa,
CFPAC1, HT 1080, and MCF7 (data not shown), the
rate was depressed to different extents. However, in
no line was entry into mitosis completely blocked for
4 hr, as in normal cells.
Do those cancer cells that enter mitosis after the acti-
vation of p38 do so because they define a subpopulation
that lacks a checkpoint response, or does anisomycin
delay G2 equally in all cells? To answer this question,
we located early prophase cells in HeLa cultures and
perfused them with anisomycin. All of these cells (n = 7)
entered mitosis with normal timing (Figure 2C). Thus,
cells that progress into mitosis after the activation of
p38 in cancer lines do so because the stress-checkpoint
response is attenuated.
Eliminating Both p53 and pRb Attenuates the
Duration of the p38-Mediated Stress Checkpoint by
Enhancing the Rate of Slippage
Because entry into mitosis is delayed 4–5 hr after the
activation of p38 in normal BJ and hTERT immortalized
(RPE1 and BJ-EN) cells, immortalization per se does
not attenuate the stress checkpoint. To determine
whether p53 is involved in this process, we treated hu-
man cells in which p53 was either genetically inactivated
(HMEC184AA2) or inactivated by human papillomavirus
type 16 (HPV-16) E6 expression (E6 keratinocytes) with
anisomycin. In these lines, anisomycin still significantly
retarded entry into mitosis, although the delay was
slightly shorter (3–4 hr versus 4–4.5 hr; cf., Figures 2A
and 3A) than in the p53+ parental controls. (Consistent
with this, we found that p21Cip1, a potent cyclin-depen-
dent kinase inhibitor regulated by p53, is not induced
when RPE1 or BJ-EN cultures are treated with anisomy-
cin [data not shown]). Thus, the stress checkpoint
remains largely functional in cells that have undergone
the two early stages of transformation (viz., telomerase
immortalization and p53 inactivation).
The inactivation of both p53 and pRb by the expres-
sion of viral oncoproteins produces full transformation
Current Biology Vol 17 No 24
2164Figure 2. Activating p38 with Anisomycin Inhibits Entry into Mitosis in Normal but Not Cancer Cells
(A and B) Graphic representations from live-cell population studies, depicting the percentage of total cells within the same microscopic field that
entered mitosis (y axis) every half hour (x axis) in the absence of p38 activation (solid line, open squares; DMSO only) and after (gray line, solid
squares) the activation of p38 at 0 time with 75 nM anisomycin. The percentages represent the average from several experiments (for n, see Table
S1)6 the standard error of the mean (SEM). Typically, 7 min elapsed between the addition of the drug to the initiation of recordings. Note that the
activation of p38 rapidly and completely inhibits entry into mitosis (the G2-M transition) for at least 4 hr in normal cells (A) but to a much lesser
extent in tumor cells (B).
(C) The behavior of normal (RPE1) and cancer (HeLa) cells after the activation of p38 with anisomycin during late G2. RPE1 (top) and HeLa (bot-
tom) cells in the early stages of chromosome condensation (arrows at 0 and 10 min, top panel) were located within a culture and followed by time-
lapse imaging. Ten minutes into imaging, the cultures were perfused with 75 nM anisomycin (see the Supplemental Experimental Procedures).
The activation of p38 in RPE1 cells rapidly arrests progression through G2 and reverses chromosome condensation (compare chromosomes at
20 versus 10 min, top panel, arrows). In contrast, after the activation of p38 in HeLa cells (bottom panel), chromosome condensation continued
normally, and nuclear-envelope breakdown (NEB) occurred, as in nontreated controls,w50 min later. The scale bar represents 10 mM.in many cell types. We found that the activation of p38 in
cultures of keratinocytes expressing HPV-16 E6 and E7,
which lack p53 and pRb, only briefly delayed the G2-M
transition (Figure 3A), and the cells resumed cyclinginto mitosisw90 min after drug treatment. Furthermore,
after 3.5 hr, the rate cells entered mitosis in these
cultures was not statistically different from that of
untreated cells (Figure 3A). To determine whether E7’s
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(A) Graphic representations from population studies (described in Figure 1) depicting the rate at which cells enter mitosis in cultures of immor-
talized mammary epithelia that contain (HMEC184A1) or lack (HMEC184AA2) a functional p53. Similar analyses were conducted on human
keratinocytes lacking functional p53 (E6) or lacking both p53 and pRB (E6E7), as well as in hTERT-immortalized BJ fibroblasts containing
(BJ-EN) or lacking (BJ-ELB) p53 and pRB or lacking p53 and pRB but expressing V12Ras (BJ-ELR). In general, the sustainability (duration) of
the G2 delay induced by the activation of p38 decreases with increasing degrees of transformation. The percentages represent the average
from several experiments (for n, see Table S1) 6 the SEM.
(B) Western blot depicting dually phosphorylated and activated p38 (p38-T*GY*) versus total p38 loading control (bottom panel) in BJ-ELR cells.
Samples were prepared 30 min after the incubation of cultures in media plus DMSO FOR 30 min or for various times in media containing 75 nM
anisomycin (dissolved in DMSO).
(C) Similar to (B) except these blots show the activity of p38 as well as its downstream target, MK2, over 8 hr. Note that in response to
anisomycin, both p38 and MK2 are strongly activated in BJ-ELR cells within the first hour but both then decline to near pretreatment levels during
the second hour.involvement in this checkpoint attenuation is due to pRb
inhibition and not E7’s acting on other substrates, we
used an E7 mutant (E7.24) that does not inhibit pRb
but that is functionally normal in all other respects [17].
For this study, we treated cultures of keratinocytes
expressing E7.24 with anisomycin and examined them
at hourly intervals. As observed in control keratinocytes,
we found that the activation of p38 in E7.24 cells blocked
entry into mitosis for at least 4 hr (data not shown). Thus,
E7 leads to stress-checkpoint attenuation by inhibiting
pRb and not other substrates.We also found that the G2-M transition was only
briefly (i.e., for w1.5 hr; Figure 3A) delayed when p38
was activated in hTERT-immortalized BJ fibroblasts
lacking p53 and pRB (BJ-ELB cells) because of SV40
large-T oncoprotein [18] or E6E7 [19] expression. How-
ever, unlike E6 and E7 keratinocytes, these fibroblasts
resumed cycling into mitosis after 1.5 hr at a very low
rate for the duration of the experiment. (A Student’s
t test comparison of the recovery rates between BJ-EN
and BJ-ELB cells during the first 3 hr of anisomycin
treatment reveals that they are significantly different,
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40-transformed cell lines, including the GM16666A
and GM16667A (NIGMS) human fibroblasts (data not
shown). Together, these observations reveal that the
elimination of p53 and pRb, with human papillomavirus
E6 and E7 and/or the large-T of SV40, can lead to signif-
icant attenuation of the p38-mediated G2 stress check-
point by enhancing the rate of slippage.
Constitutive Ras Signaling Further Attenuates the
p38 Stress Checkpoint in Cells Lacking pRB and p53
Mutations that constitutively activateRas are frequent in
cancers and lead to high ERK1 and 2 activity [20]. Some
tumor lines used in our study exhibit high ERK activity
(T-HEP3, CFPAC1), and some harbor constitutively acti-
vated Ras (CFPAC1, HT-1080). ERK is constitutively ac-
tivated when H-RasV12 is introduced into BJ-ELB (-p53
and -pRb) fibroblasts [19], and the resultant BJ-ELR cells
become fully tumorigenic [18]. We found that BJ-ELR
cells responded slower to p38 activation than did their
parental (BJ-ELB) controls, exhibiting only a 50% reduc-
tion in the number of cells entering mitosis after 30 min
(Figure 3A). Furthermore, unlike what was observed in
control cells, the activation of p38 never prevented all
BJ-ERL cells from entering mitosis because even after
1 hr, 0.036 0.03% of the cells continued to cycle into di-
vision, and this rate progressively increased after 30 min
until it approached control levels 4 hr later (Figure 3A).
Given this result, it became important to determine
the extent to which anisomycin activates p38 in Ras-
expressing BJ-ELR cells. Constitutive Ras activity does
not prevent p38 activation in immortal p53-pRB cells
[19], and stress activates p38 in oncogenic Ras-ex-
pressing cells, in which ERK is constitutively active
[21]. Not surprisingly, therefore, we found (Figure 3C)
that a 5 min treatment with 75 nM anisomycin produced
an w10-fold increase in p38 activity in BJ-ERL cells,
which greatly exceeded that seen in normal BJ-EN cells
(Figure S3), after which it decayed to levels near back-
ground. Thus, as in HeLa (Figure 1), the attenuation of
the G2 stress checkpoint in BJ-ELR fibroblasts is due
to a disruption between p38 and its cdc25 and CDK1
target.
Together, these data reveal that the activation of p38
in fully transformed (BJ-ELR) fibroblasts briefly and in-
completely inhibits the G2-M transition. Moreover,
because BJ-ELR fibroblasts, T-Hep3 (Figure 2B), and
E6E7 keratinocytes (Figure 3A) cycle into mitosis at rel-
atively normal rates 4–5 hr after anisomycin treatment,
the drug-induced reduction in protein synthesis is insuf-
ficient during this period to prevent the G2-M transition.
ERK1 and 2 Kinase Activity Is Required for the
Ras-Mediated Attenuation of the Stress Checkpoint
in Cells Lacking pRB and p53
The ERK1 and 2 group of MAP kinases promotes cell-
cycle progression after radiation-induced DNA damage
[22], and high ERK1 and 2 activity is necessary for Ras-
induced chromosomal instability [23]. This prompted us
to ask whether hyperfunction of the Ras-Raf-MEK1 and
2-ERK1 and 2 signaling cascade participates in attenu-
ating the stress checkpoint in BJ-ELR cells. To answer
this question, we blocked ERK activity in these cells be-
fore activating p38. Because the H-Ras-V12 oncogenesignificantly enhances ERK1 and 2 activity in BJ-ELR
cells [19], these cells required higher inhibitor concen-
trations than nontransformed cells to suppress ERK1
and 2. In this regard, we found that a 3 hr treatment
with 400 mM U0126 completely inhibited ERK1 and 2 in
BJ-ELR cells for at least 7 hr (Figure 4A). As expected
[11], U0126 slightly depressed p38 activity during the
first 3 hr, but this returned to control levels by the fourth
hour (Figure 4A). During the first 5 hr in U0126, the rate at
which BJ-ELR cells entered mitosis was also nominally
depressed, but it too returned to control levels after
this time (the 2 hr mark in Figure 4A0). (Because we
also observed this transient decrease in the rate at
which BJ-ELR cells enter mitosis in response treatment
with a nonfunctional analog of U0126 (U0124; Fig-
ure 4B0), we attribute it to nonspecific effects.) Impor-
tantly, however, we found that when BJ-ELR cultures
were treated with anisomycin 3 hr after the inhibition of
ERK1 and 2 with U0126, the rate at which cells entered
mitosis dropped to zero for 3 hr (Figure 4A0).
We then repeated this experiment with U0124, an in-
active analog of U0126, and found that anisomycin treat-
ment neither reduced ERK1 and 2 activity (Figure 4B) nor
delayed entry into mitosis any more than did anisomycin
treatment alone (cf. Figures 3A, 4A0, and 4B0). Thus,
excessive ERK1 and 2 activity in cells constitutively
expressing the Ras oncogene contributes to the attenu-
ation of the p38 stress checkpoint. Additional work
with CI-1040, a much more potent and specific ERK1
and 2 inhibitor [24], further substantiated this conclusion
(Figures 4C and 4C0): Simply the reduction of ERK1 and 2
activity in BJ-ELR cells to levels seen in nontransformed
cells during late G2 [25] also prolongs the G2 block
induced by the activation p38.
MAPKAP kinase-2 (MK2) is the major downstream
target of the p38 pathway. Activated MK2 can modify
gene expression [26], depress translation [27], and delay
G2 progression independent of the Chk1 kinase by indi-
rectly inhibiting the Cdc25 phosphatase [28]. To deter-
mine whether stress-checkpoint abrogation in BJ-ELR
(and other transformed) cells results from a failure of
p38 to activate MK2, we assayed MK2 levels after acti-
vating p38. As for p38, we found that MK2 is strongly
but transiently (1 hr) activated by anisomycin in BJ-ELR
and other cancer cells (Figure S3). The fact that 75 nM
anisomycin induces both a 1 hr activation of MK2 (Fig-
ure 3D) and an w1 hr G2 delay in BJ-ELR (Figure 3A)
suggests that the duration of the stress checkpoint is
defined by MK2 activity. This is consistent with the
report that the sustained (more than 8 hr) activation of
p38 and MK2 induced by doxorubicin (a topoisomerase
II inhibitor) in U2OS cells produces a sustained (more
than 8 hr) S-G2 arrest [28]. However, in RPE1 cells,
75 nM anisomycin leads to an w2 hr activation of MK2
(Figure S3), yet it produces a 4 hr delay in G2 (Figure 2).
Clearly, the role of MK2 in regulating the duration of the
stress checkpoint requires further study.
In summary, relative to normal cells, the p38-mediated
stress checkpoint is attenuated in transformed cells.
Although our data implicate Ras signaling and ERK1
and 2 activity in the attenuation process, how these
pathways ultimately disrupt the Cdc25-mediated [3,
29] suppression of CDK1 to effect a G2 delay remains
unclear. In retrospect, the loss of the stress checkpoint
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2167Figure 4. ERK1 and 2 Activity Participates in Attenuating the p38-Mediated G2 Delay in BJ-ELR Cells
(A) Western blot showing that a 3 hr treatment with 400 mM U0126 completely inhibits ERK1 and 2 activity in BJ-ELR cells and, although it also
initially depresses p38 activity, p38 activity returns to normal levels by 4 hr.
(A0) Graphic representation from population studies depicting the rate that BJ-ELR cells enter mitosis 3 hr after inhibiting ERK1 and 2 with 200 mM
U0126 with (gray line, solid boxes) and without (dashed line, open triangles) a subsequent treatment (at time 0) with 75 nM anisomycin. Note that
the inhibition of ERK1 and 2 before the activation of p38 leads to a complete cessation of mitotic entry in BJ-ELR cells for at least 2 hr (cf.
Figure 3A).
(B and B0) Same conditions as in (A) and (A0) except that U0126 was replaced by its inactive analog, U0124 (400 mM). Note that this analog neither
inhibits ERK1 and 2 nor prolongs the G2 block after the activation of p38 with anisomycin (cf. Figure 4A).
(C and C0) Same conditions as in (A) and (A0) except that U0126 was replaced by 600 nM CI-1040, a more potent and specific ERK1 and 2 inhibitor.
The concentration of CI-1040 used in this study reduced ERK1 and 2 activity to that which approximates the level seen in normal G2 cells [25].
Under this condition, the activation of p38 with anisomycin completely inhibits entry into mitosis for at least 2 hr (cf. Figure 4A).
The percentages represent the average from several experiments (for n, see Table S1) 6 the SEM.during transformation is not unexpected: Any mutation
in a cell-cycle brake will confer a selective growth
advantage over normal cells, and mutations(s) in a brake
activated by stress will, by Darwinian selection [30],
make it easier for the cell to outgrow normal cells under
the increasingly stressful conditions (e.g., hypoxia, high
pH, etc.) in a tumor. This is likely true also for cells in
culture, where mutations in tumor suppressers like
pRb or p53 promote, over generations, genetic changes
that provide a selective growth advantage under stress.
Epithelial cancers induced by chronic environmental
stress, notably Barrett’s esophageal and cervical dys-
plasias, are well known clinical examples. At this time,
the clinical relevance of our conclusions remains
unclear, but because our data implicates the ERK1
and 2 MAPK pathway in stress-checkpoint attenuation,
ERK1 and 2 inhibitors (which are under clinical trials)
might slow the growth of tumor cells by potentiating
the stress checkpoint.Supplemental Data
Experimental Procedures, four figures, and one table are available at
http://www.current-biology.com/cgi/content/full/17/24/2162/DC1/.
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